Millie
your market intelligence analyst
Search Results
127 results
Your search is now limited to «Celgene» expert search.
FiercePharmaManufacturing 07/19/2019 09:22
As filgotinib filing nears, Gilead should nab Celgene's Otezla, analysts say.
More from FiercePharmaManufacturing:
Seeking Alpha 07/18/2019 10:21
Under the takeover terms, Celgene shareholders receive one Bristol-Meyers Squibb ["BMS"] share, plus $50 cash, total value $94.45, $2.92 higher than the current Celgene price.
More from Seeking Alpha:
PharmiWeb.com 07/18/2019 06:00
According to a newly published report by market.us, “Worldwide Myelodysplastic Syndrome (MDS) Treatment Market: Information About Key Drivers, Restraints, And Opportunities 2019-2028“. The prime objective of the report is to deliver a Ten-year (2019-2028) market forecast. The latest study focusing on myelodysplastic syndrome (mds) treatment market with topmost companies, to determine, define and analyses the sales size, value, market share, market competition landscape, and recent development. I…
More from PharmiWeb.com:
FierceBiotech 07/16/2019 14:14
GNS Healthcare's AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene.
More from FierceBiotech:
Business Wire 07/16/2019 08:30
Zymeworks will receive a US$7.5 million payment as a result of Celgene’s exercise of its option to a commercial license.
More from Business Wire:
NASDAQ 07/15/2019 20:09
Celgene CELG closed the most recent trading day at 91 76 moving 0 18 from the previous trading session This change lagged the S amp P 500 s daily gain of 0 02 Elsewhere the Dow gained 0 1 while the tech heavy Nasdaq added 0 17 Prior to today s trading shares of the.
More from NASDAQ:
ENDPOINTS 07/09/2019 09:27
Celgene’s BD team is staying in gear ahead of the close of the $74 billion Bristol-Myers buyout.
More from ENDPOINTS:
FierceMedicalDevices 07/09/2019 07:40
Celgene has expanded its deal with Nimbus Therapeutics to secure an option on an HPK1 inhibitor program.
More from FierceMedicalDevices:
On 27 June 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Azacitidine Celgene, intended for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukemia.
More from European Medicines Agency - EMEA (EU):
Bristol-Myers Squibb (BMS) is planning to divest Celgene’s psoriasis drug Otezla (apremilast), in a bid to expedite the process of merger with Celgene.
More from Pharmaceutical Business Review:
Pharmafile 06/24/2019 12:01
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators.
More from Pharmafile:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications